AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie UTB by Year
UTB — Portion That Would Affect Effective Tax Rate ($M) ($M)
AbbVie UTB: $4,400M in FY2025, up 2.3% from a year earlier.
Latest, FY2025
4,400
Period ended Dec 31, 2025
Change on a year earlier
+2.3%
4,300 in FY2024
History
11 years
Since FY2015
Sources
10
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 14 Income Taxes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | UTB — Portion That Would Affect Effective Tax Rate ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,400 | +2.3% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 4,300 | -23.2% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 5,600 | +1.8% | Form 10-K (filed 2025-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 5,500 | +5.8% | Form 10-K (filed 2024-02-20) ↗ |
| FY2021 | Dec 31, 2021 | 5,200 | +4.0% | Form 10-K (filed 2023-02-17) ↗ |
| FY2020 | Dec 31, 2020 | 5,000 | +108.3% | Form 10-K (filed 2022-02-18) ↗ |
| FY2019 | Dec 31, 2019 | 2,400 | -11.1% | Form 10-K (filed 2021-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 2,700 | +3.8% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 2,600 | +136.4% | Form 10-K (filed 2019-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 1,100 | +22.1% | Form 10-K (filed 2018-02-16) ↗ |
| FY2015 | Dec 31, 2015 | 901 | – | Form 10-K (filed 2017-02-17) ↗ |
Cite this data
StockData. (2026). AbbVie UTB ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/utb-etr-impact
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.